Usana Health Sciences Financials

Usana Health Sciences Inc

USNANYSE

Trade with Public

$14.96

0.533.67%

가까이에: Sep 4, 5:00 PM EST

$14.96

N/A

시간외: 4:00 PM EST

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

Usana Health Sciences Financials

Usana Health Sciences (USNA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Usana Health Sciences Lowers FY2026 Adj EPS Guidance from $1.95-$2.29 to $0.76 vs $2.12 Est; Lowers FY2026 Sales Guidance from $925.000M-$1.000B to $910.000M vs $945.097M Est

Usana Health Sciences (NYSE:USNA) lowers FY2026 Adj EPS guidance from $1.95-$2.29 to $0.76 vs $2.12 analyst estimate. Lowers FY2026 sales outlook from $925.000 million-$1.000 billion to $910.000 million vs $945.097

Benzinga Newsdesk

PRO
Usana Health Sciences Q2 Adj. EPS $(0.07) Misses $0.43 Estimate, Sales $223.273M Miss $235.003M Estimate

Usana Health Sciences (NYSE:USNA) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.43 by 116.28 percent. This is a 109.46 percent decrease over earnings of $0.74 per share

Benzinga Newsdesk

PRO
Usana Health Sciences Affirms FY2026 GAAP EPS Guidance of $1.11-$1.45 vs $1.11 Est

Benzinga Newsdesk

PRO
Usana Health Sciences Affirms FY2026 Adj EPS Guidance of $1.95-$2.29 vs $1.95 Est; Affirms FY2026 Sales Guidance of $925.000M-$1.000B vs $938.739M Est

Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights

Usana Health Sciences Q4 Earnings Assessment

Benzinga Insights

Usana Health Sciences Inc

Usana Health Sciences Financials

Earnings & Guidance News

PRO
Usana Health Sciences Lowers FY2026 Adj EPS Guidance from $1.95-$2.29 to $0.76 vs $2.12 Est; Lowers FY2026 Sales Guidance from $925.000M-$1.000B to $910.000M vs $945.097M Est

PRO
Usana Health Sciences Q2 Adj. EPS $(0.07) Misses $0.43 Estimate, Sales $223.273M Miss $235.003M Estimate

PRO
Usana Health Sciences Affirms FY2026 GAAP EPS Guidance of $1.11-$1.45 vs $1.11 Est

PRO
Usana Health Sciences Affirms FY2026 Adj EPS Guidance of $1.95-$2.29 vs $1.95 Est; Affirms FY2026 Sales Guidance of $925.000M-$1.000B vs $938.739M Est

Earnings Scheduled For May 5, 2026

Usana Health Sciences Q4 Earnings Assessment

뉴스

파트너 / 기고자

벤징가 글로벌

Benzinga

Benzinga

Benzinga

Usana Health Sciences Inc

Usana Health Sciences Financials

Earnings & Guidance News

PROUsana Health Sciences Lowers FY2026 Adj EPS Guidance from $1.95-$2.29 to $0.76 vs $2.12 Est; Lowers FY2026 Sales Guidance from $925.000M-$1.000B to $910.000M vs $945.097M Est

PROUsana Health Sciences Q2 Adj. EPS $(0.07) Misses $0.43 Estimate, Sales $223.273M Miss $235.003M Estimate

PROUsana Health Sciences Affirms FY2026 GAAP EPS Guidance of $1.11-$1.45 vs $1.11 Est

PROUsana Health Sciences Affirms FY2026 Adj EPS Guidance of $1.95-$2.29 vs $1.95 Est; Affirms FY2026 Sales Guidance of $925.000M-$1.000B vs $938.739M Est

Earnings Scheduled For May 5, 2026

Usana Health Sciences Q4 Earnings Assessment

Benzinga

뉴스

파트너 / 기고자

벤징가 글로벌

PRO
Usana Health Sciences Lowers FY2026 Adj EPS Guidance from $1.95-$2.29 to $0.76 vs $2.12 Est; Lowers FY2026 Sales Guidance from $925.000M-$1.000B to $910.000M vs $945.097M Est

PRO
Usana Health Sciences Q2 Adj. EPS $(0.07) Misses $0.43 Estimate, Sales $223.273M Miss $235.003M Estimate

PRO
Usana Health Sciences Affirms FY2026 GAAP EPS Guidance of $1.11-$1.45 vs $1.11 Est

PRO
Usana Health Sciences Affirms FY2026 Adj EPS Guidance of $1.95-$2.29 vs $1.95 Est; Affirms FY2026 Sales Guidance of $925.000M-$1.000B vs $938.739M Est